Understanding CD137-CD137L Signaling in Type 1 Diabetes
Mechanistic and therapeutic role of the CD137-CD137L axis in Type 1 Diabetes
['FUNDING_R01'] · MEDICAL COLLEGE OF WISCONSIN · NIH-11123344
This research explores how specific immune signals, called CD137 and CD137L, work in Type 1 Diabetes to find new ways to manage the condition.
Quick facts
| Phase | ['FUNDING_R01'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | MEDICAL COLLEGE OF WISCONSIN (nih funded) |
| Locations | 1 site (MILWAUKEE, UNITED STATES) |
| Trial ID | NIH-11123344 on ClinicalTrials.gov |
What this research studies
Our immune system has complex signals that can sometimes mistakenly attack the body's own cells, as seen in Type 1 Diabetes. This research focuses on two key immune signals, CD137 and CD137L, and how they communicate within different immune cells. We are learning how these signals influence the progression of Type 1 Diabetes and how they might be controlled. Specifically, we are looking at a molecule called soluble CD137 (sCD137), which appears to calm down the immune system. Understanding these details could lead to new treatments that protect the insulin-producing cells in the pancreas.
Who could benefit from this research
Good fit: This research is relevant for individuals living with or at risk for Type 1 Diabetes, as it seeks to understand the underlying immune processes of the disease.
Not a fit: Patients whose conditions are not related to autoimmune processes or Type 1 Diabetes would not directly benefit from this specific research.
Why it matters
Potential benefit: If successful, this work could lead to new therapies that slow or stop the immune attack on the pancreas in people with Type 1 Diabetes.
How similar studies have performed: Preliminary studies in animal models have shown that manipulating this immune system, specifically with soluble CD137, can improve acute Type 1 Diabetes.
Where this research is happening
MILWAUKEE, UNITED STATES
- MEDICAL COLLEGE OF WISCONSIN — MILWAUKEE, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: CHEN, YI-GUANG — MEDICAL COLLEGE OF WISCONSIN
- Study coordinator: CHEN, YI-GUANG
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.